Pneumococcal pneumonia is a potentially serious bacterial lung disease that can disrupt your life for weeks and even land you in the hospital. Medical experts want you to know that there are steps you ...

Actor Val Kilmer, 65, died of pneumonia this week, his daughter confirmed. Dr. Marc Siegel discusses common causes and risks ...

Pneumococcal infections can be very serious – they include pneumonia, meningitis, and bacteremia (a blood infection), as well as usually less worrying ear infections and sinus infections. To protect ...

Vaxcyte is awaiting data from another vaccine candidate for invasive pneumococcal disease (IPD) before advancing to Phase III ...

(Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the ...

There are around 100 different pneumococcal serotypes, causing non-invasive disease like pneumonia, confined to the lungs, and invasive disease, where the infection can spread to the bloodstream ...

"Given the vast unmet public health needs in invasive pneumococcal disease (IPD), we’re delighted to expand this collaboration and continue our pursuit of innovative work in PCV," remarked ...

To get the word out about the expanded guidelines and the risk of pneumococcal disease, Pfizer this month launched a campaign focused on reaching the 50-plus crowd via social and digital channels ...

Healthcare providers, public health officials and policymakers need to develop a greater understanding of the serious health impact of pneumococcal disease in elderly adults. In addition to ...

MSD has received approval from the European Commission (EC) for Capvaxive, a pneumococcal 21-valent conjugate vaccine, to prevent invasive disease and pneumonia due to Streptococcus pneumoniae ...

Merck (MRK), known as MSD outside of the United States and Canada, announced that the European Commission, or EC, has approved CAPVAXIVE, or Pneumococcal 21-valent Conjugate Vaccine, for active ...

The magnitude of disease impact did not differ among schedules. Evidence for impact on pneumococcal pneumonia and empyema varied. Conclusions: All schedules (2+1, 3+0 and 3+1) reduced clinical and ...